rabeprazole

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma

Conditions

Asthma, Gastroesophageal Reflux Disease

Trial Timeline

Sep 1, 2002 โ†’ Mar 1, 2005

About rabeprazole

rabeprazole is a phase 3 stage product being developed by Eisai for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00214552. Target conditions include Asthma, Gastroesophageal Reflux Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00222170Phase 2Completed
NCT00214552Phase 3Completed